View PDF Version - RePub - Erasmus Universiteit Rotterdam

More documents

Recommendations

Info

Chapter 4.2 202 release. Although we cannot rule out a possible effect of tenofovir on blocking infection (η varying between 0 and 100%), the viral kinetic data for ten ofovir could be fi tted assuming both effects (η = 1 and η = 0). The HBV-DNA levels can fl uctuate even in untreated pa tients. However, pretreatment levels of HBV-DNA in the patients in our study were similar to t = 0. This suggests that the rapid decrease in HBV-DNA levels after t = 0 could be attributed to treatment with tenofovir, and was not the consequence of a spontaneous decrease. In our study, 4 weeks after addition of tenofovir to the treatment regimen, a mean log HBV-DNA decline of 2.54 ± 0.91 (median 2.34; range: 1.33 4.02) could be observed. This is comparable with the 2.42 log HBV-DNA decline found in a study with tenofovir in fi ve HIV/HBV co infected resistant patients, 12 and is higher than the 0.9 log HBV-DNA decline in a study performed in 12 HIV/ HBV co-infected patients who were treated with tenofovir. 11 Taken together, the data which showed a mean log HBV-DNA decline of 4.95 ± 0.90 log HBV-DNA (median 5.05; range: 3.64 5.94) after 24 weeks of tenofovir in our study and the data which showed a mean log decline of 3.4 copies/ mL after 24 weeks treatment with adefovir in lamivudine resistant HIV/HBV co-infected patients, 27 suggests that tenofovir may have an important role to play in patients who experience breakthrough viraemia on lamivudine therapy. The second-phase decline in viral levels refl ects the death rate of productively infected cells. The death of these cells is thought to require a host immune response. A possible marker of the strength of host immune response is the level of ALT, which is an indicator of the level of cell damage and death. Previously, authors have observed a positive correlation between the decay rate of infected cells and the pretreatment ALT level among chronic HBV patients who were treated with lamivudine therapy. 25 Another study, which analysed the infl uence of lamivudine dose and baseline ALT on the viral dynamics of the HBV, confi rmed that higher baseline ALT levels were signifi cantly related to the slope of the second-phase of viral decay. 28 Nevertheless, in another study, in which patients were treated with either lamivudine monotherapy or with a combination of lamivudine and famciclovir, the investigators found no association between the slope of the second-phase and baseline ALT. 29 This is in agreement with our study, in which kinetic parameters λ1 , λ2 and e were not associated with the pretreatment ALT levels. This discrepancy with some other studies may be explained by the selection of patients in our study, which included patients with only moderate elevation of ALT. We speculate that the ALT levels were too low to produce a detectable association with the slope of viral decay.
Viral dynamics during tenofovir therapy 203 Our data demonstrate that direct comparison of the effi cacies given by different mathematical models is not always possible. As we have demonstrated, variations between the models with respect to sampling frequencies and duration of follow up result in different outcomes. In addition, our data show that tenofovir is capable of effectively blocking viral replication in patients with lamivudine-induced mutant viruses in both HBV and HBV/ HIV co-infected patients. However, for effective treatment of patients, the first goal should be to totally inactivate disease by completely blocking virion production. In terms of modelling this will mean an antiviral effi cacy ‘ε’ equivalent to 1. Our results show that, in patients with lamivudine-induced drug-resistant mutants, we can reach an effi cacy of 0.99. Therefore, despite the drug having an excellent effect, our data also show some low-grade viral replication remains. We suggest that the residual replication may present a risk for genotypic succession during tenofovir therapy.
Page 1:
Statistical Models of Treatment Eff
Page 4 and 5:
ISBN: 978-90-8559-069-9 © Bettina
Page 6 and 7:
PROMOTIECOMMISSIE Promotor: Prof.dr
Page 9 and 10:
CONTENTS Chapter 1. Introduction 11
Page 13:
Cha pter 1 Introduction
Page 16 and 17:
Chapter 1 14 Epidemiology Worldwide
Page 18 and 19:
Chapter 1 16 Prediction models with
Page 20 and 21:
Chapter 1 18 standard method fails
Page 22 and 23:
Chapter 1 20 The extended non-linea
Page 24 and 25:
Chapter 1 22 References 1. Blumberg
Page 27:
Cha pter 2 Prediction of response t
Page 30 and 31:
Chapter 2.1 28 ABSTRACT The aim of
Page 32 and 33:
Chapter 2.1 30 been hepatitis B sur
Page 34 and 35:
Chapter 2.1 32 HBV DNA decline The
Page 36 and 37:
Chapter 2.1 34 Figure 2 continued.
Page 38 and 39:
Chapter 2.1 36 Figure 4. Estimated
Page 40 and 41:
Chapter 2.1 38 DNA was observed in
Page 42:
Chapter 2.1 40 15. Kao JH. Role of
Page 46 and 47:
Chapter 2.2 44 ABSTRACT Background:
Page 48 and 49:
Chapter 2.2 46 low baseline HBV DNA
Page 50 and 51:
Chapter 2.2 48 patient subgroups wa
Page 52 and 53:
Chapter 2.2 50 p=0.002). Previous I
Page 54 and 55:
Chapter 2.2 52 Application of the m
Page 56 and 57:
Chapter 2.2 54 PEG-IFN, the proport
Page 58 and 59:
Chapter 2.2 56 References 1. Lavanc
Page 60 and 61:
Chapter 2.2 58 26. Bonino F, Lau GK
Page 63 and 64:
Chap ter 2.3 Prediction of the resp
Page 65 and 66:
INTRODUCTION Dynamic prediction of
Page 67 and 68:
Statistical analysis Dynamic predic
Page 69 and 70:
Dynamic prediction of response to P
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
References Dynamic prediction of re
Page 81 and 82:
Cha pter 2.4 Dynamic prediction of
Page 83 and 84:
INTRODUCTION Dynamic prediction of
Page 85 and 86:
For the indirect approach we rewrit
Page 87 and 88:
logit pi,j = logit Pr(Ri =1|visit =
Page 89 and 90:
Dynamic prediction of response usin
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Table 1. Results of different stopp
Page 103 and 104:
Page 105:
Page 108 and 109:
Chapter 2.5 106 ABSTRACT Peginterfe
Page 110 and 111:
Chapter 2.5 108 and placebo daily.
Page 112 and 113:
Chapter 2.5 110 for patients with a
Page 114 and 115:
Chapter 2.5 112 Mean HBV DNA declin
Page 116 and 117:
Chapter 2.5 114 peginterferon and n
Page 118 and 119:
Chapter 2.5 116 hepatocellular carc
Page 120 and 121:
Chapter 2.5 118 13. Werle-Lapostoll
Page 122:
Chapter 2.5 120 Greece - G Germanid
Page 127 and 128:
Chap ter 3.1 Long-term clinical out
Page 129 and 130:
INTRODUCTION Glycyrrhizin for IFN-n
Page 131 and 132:
Statistics Glycyrrhizin for IFN-non
Page 133 and 134:
Glycyrrhizin for IFN-non responders
Page 135 and 136:
Table 2. Time dependent Cox regress
Page 137 and 138:
Page 139 and 140:
Page 143 and 144:
Cha pter 3.2 Discriminant analysis
Page 145 and 146:
Introduction Discriminant analysis
Page 147 and 148:
Discriminant analysis using a MLMM
Page 149 and 150:
Estimation Discriminant analysis us
Page 151 and 152:
Discriminant analysis using a MLMM
Page 153 and 154: where wi,k(y i, θ) = (k =1,...,K).
Page 155 and 156: Discriminant analysis using a MLMM
Page 171 and 172: Appendix Discriminant analysis usin
Page 175: Cha pter 4 Statistical models of ea
Page 178 and 179: Chapter 4.1 176 ABSTRACT Nucleoside
Page 180 and 181: Chapter 4.1 178 at day 1 at t =0 an
Page 182 and 183: Chapter 4.1 180 Table 1. Baseline c
Page 184 and 185: Chapter 4.1 182 Figure 1.
Page 186 and 187: Chapter 4.1 184 Figure 1. Viral dec
Page 188 and 189: Chapter 4.1 186 suppression in seru
Page 190 and 191: Chapter 4.1 188 13. Seifer M, Hamat
Page 193 and 194: Cha pter 4.2 Viral dynamics during
Page 195 and 196: INTRODUCTION Viral dynamics during
Page 197 and 198: Viral dynamics during tenofovir the
Page 201 and 202: log HBV DNA (copies/mL) 10.0 9.0 8.
Page 203: Viral dynamics during tenofovir the
Page 211 and 212: Chap ter 4.3 Modelling of early vir
Page 213 and 214: INTRODUCTION HBV viral kinetics dur
Page 215 and 216: HBV viral kinetics during PEG-IFN 2
Page 229: HBV viral kinetics during PEG-IFN 2
Page 233 and 234: SUMMARY AND CONCLUSION Summary and
Page 235 and 236: Summary and conclusion 233 The mode
Page 237 and 238: Summary and conclusion 235 The infe
Page 239: Summary and conclusion 237 Early st
Page 243 and 244: SAMENVATTING EN CONCLUSIE Samenvatt
Page 245 and 246: Samenvatting en conclusie 243 Er we
Page 247 and 248: Samenvatting en conclusie 245 Data
Page 249 and 250: Samenvatting en conclusie 247 Behan
Page 253: Dan kwoord
Page 256 and 257:
Dankwoord 254 Lieve Marion en Margr
Page 259 and 260:
BIBLI OGRAPHY Bibliography 257 1. K
Page 261 and 262:
Bibliography 259 Interferon-ribavir
Page 263 and 264:
Bibliography 261 Long term clinical
Page 265 and 266:
Bibliography 263 Flares in chronic
Page 267 and 268:
Bibliography 265 Genetic characteri
Page 269:
Bibliography 267 106. Reijnders JG,
show all

View PDF Version - RePub - Erasmus Universiteit Rotterdam

Create successful ePaper yourself

Delete template?

Save as template?